(AZTA) Azenta - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.042m USD | Total Return: -25.4% in 12m

Sample Management, Automation, Cryogenics, Genomics, Analysis
Total Rating 30
Safety 91
Buy Signal -1.23
Medical Instruments & Supplies
Industry Rotation: -9.7
Market Cap: 1.04B
Avg Turnover: 21.5M USD
ATR: 5.59%
Peers RS (IBD): 15.0
Risk 5d forecast
Volatility74.8%
Rel. Tail Risk-21.4%
Reward TTM
Sharpe Ratio-0.27
Alpha-64.90
Character TTM
Beta1.502
Beta Downside1.059
Drawdowns 3y
Max DD70.52%
CAGR/Max DD-0.31
EPS (Earnings per Share) EPS (Earnings per Share) of AZTA over the last years for every Quarter: "2021-03": 0.61, "2021-06": 0.72, "2021-09": 0.78, "2021-12": 0.12, "2022-03": 0.12, "2022-06": 0.12, "2022-09": 0.16, "2022-12": 0.12, "2023-03": -0.06, "2023-06": 0.13, "2023-09": 0.13, "2023-12": 0.02, "2024-03": 0.05, "2024-06": 0.16, "2024-09": 0.18, "2024-12": 0.08, "2025-03": 0.05, "2025-06": 0.19, "2025-09": 0.21, "2025-12": 0.09, "2026-03": 0,
EPS CAGR: -23.01%
EPS Trend: 2.8%
Last SUE: -3.39
Qual. Beats: 0
Revenue Revenue of AZTA over the last years for every Quarter: 2021-03: 129.535, 2021-06: 129.086999, 2021-09: 136.939, 2021-12: 139.652, 2022-03: 145.544, 2022-06: 132.735, 2022-09: 137.568, 2022-12: 178.366, 2023-03: 148.401, 2023-06: 165.948, 2023-09: 172.357, 2023-12: 141.725, 2024-03: 136.355, 2024-06: 144.292, 2024-09: 150.604, 2024-12: 147.436, 2025-03: 143.418, 2025-06: 143.942, 2025-09: 159.192, 2025-12: 148.642, 2026-03: null,
Rev. CAGR: 0.56%
Rev. Trend: 1.4%
Last SUE: 0.05
Qual. Beats: 0

Warnings

Volatile

Tailwinds

No distinct edge detected

Description: AZTA Azenta

Azenta Inc. (NASDAQ: AZTA) delivers end-to-end sample management and multi-omics services for life-science researchers worldwide, operating through two primary segments: Sample Management Solutions-offering automated storage, cryogenic systems, consumables, and consulting-and Multiomics, which provides gene-sequencing, synthesis, and related analytics.

In its FY 2023 results, Azenta reported revenue of $1.13 billion, a 12 % year-over-year increase, and a gross margin of 38 %. The balance sheet showed cash and cash equivalents of $420 million, supporting ongoing R&D and expansion initiatives.

Growth is being driven by rising demand for high-throughput biobanking and the accelerating adoption of omics technologies across pharma and academic labs-trends that have lifted the Life Sciences Tools & Services sector to a 9 % annual CAGR over the past three years. Azenta’s strategic partnership with Frontier Space Ltd. to run experiments in microgravity further differentiates its service offering. For deeper insight, you might explore Azenta’s profile on ValueRay.

Headlines to Watch Out For
  • Biotech R&D spending drives sample management demand
  • Genomic sequencing services revenue growth
  • Automated lab equipment sales increase
  • Strategic space partnership expands research capabilities
Piotroski VR‑10 (Strict) 4.0
Net Income: -57.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.25 > 1.0
NWC/Revenue: 86.14% < 20% (prev 111.3%; Δ -25.12% < -1%)
CFO/TA 0.03 > 3% & CFO 63.2m > Net Income -57.8m
Net Debt (-303.1m) to EBITDA (53.9m): -5.62 < 3
Current Ratio: 2.92 > 1.5 & < 3
Outstanding Shares: last quarter (45.9m) vs 12m ago 0.66% < -2%
Gross Margin: 45.30% > 18% (prev 0.46%; Δ 4.48k% > 0.5%)
Asset Turnover: 28.92% > 50% (prev 28.35%; Δ 0.57% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 7.86
A: 0.25 (Total Current Assets 779.9m - Total Current Liabilities 267.2m) / Total Assets 2.07b
B: 0.68 (Retained Earnings 1.40b / Total Assets 2.07b)
C: -0.00 (EBIT TTM -2.83m / Avg Total Assets 2.06b)
D: 3.85 (Book Value of Equity 1.38b / Total Liabilities 359.6m)
Altman-Z'' Score: 7.86 = AAA
Beneish M -2.87
DSRI: 1.17 (Receivables 186.1m/155.0m, Revenue 595.2m/578.7m)
GMI: 1.00 (GM 45.30% / 45.53%)
AQI: 1.08 (AQ_t 0.52 / AQ_t-1 0.48)
SGI: 1.03 (Revenue 595.2m / 578.7m)
TATA: -0.06 (NI -57.8m - CFO 63.2m) / TA 2.07b)
Beneish M-Score: -2.87 (Cap -4..+1) = A
What is the price of AZTA shares? As of April 08, 2026, the stock is trading at USD 21.71 with a total of 955,836 shares traded.
Over the past week, the price has changed by +2.74%, over one month by -6.14%, over three months by -42.12% and over the past year by -25.40%.
Is AZTA a buy, sell or hold? Azenta has received a consensus analysts rating of 3.43. Therefor, it is recommend to hold AZTA.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AZTA price?
Analysts Target Price 38.7 78.1%
Azenta (AZTA) - Fundamental Data Overview as of 04 April 2026
P/E Trailing = 39.0172
P/E Forward = 30.8642
P/S = 1.7518
P/B = 0.6079
P/EG = 0.5263
Revenue TTM = 595.2m USD
EBIT TTM = -2.83m USD
EBITDA TTM = 53.9m USD
Long Term Debt = 54.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.78m USD (from shortTermDebt, last fiscal year)
Debt = 108.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -303.1m USD (recalculated: Debt 108.9m - CCE 412.0m)
Enterprise Value = 739.2m USD (1.04b + Debt 108.9m - CCE 412.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -2.83m / Interest Expense TTM 0.0)
 EV/FCF = 23.90x (Enterprise Value 739.2m / FCF TTM 30.9m)
FCF Yield = 4.18% (FCF TTM 30.9m / Enterprise Value 739.2m)
FCF Margin = 5.20% (FCF TTM 30.9m / Revenue TTM 595.2m)
Net Margin = -9.71% (Net Income TTM -57.8m / Revenue TTM 595.2m)
Gross Margin = 45.30% ((Revenue TTM 595.2m - Cost of Revenue TTM 325.6m) / Revenue TTM)
Gross Margin QoQ = 42.86% (prev 45.40%)
Tobins Q-Ratio = 0.36 (Enterprise Value 739.2m / Total Assets 2.07b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 108.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.23m (EBIT -2.83m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.92 (Total Current Assets 779.9m / Total Current Liabilities 267.2m)
Debt / Equity = 0.06 (Debt 108.9m / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = -5.62 (Net Debt -303.1m / EBITDA 53.9m)
Debt / FCF = -9.80 (Net Debt -303.1m / FCF TTM 30.9m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.81% (Net Income -57.8m / Total Assets 2.07b)
RoE = -3.39% (Net Income TTM -57.8m / Total Stockholder Equity 1.70b)
RoCE = -0.16% (EBIT -2.83m / Capital Employed (Equity 1.70b + L.T.Debt 54.5m))
 RoIC = -0.13% (negative operating profit) (NOPAT -2.23m / Invested Capital 1.70b)
 WACC = 10.19% (E(1.04b)/V(1.15b) * Re(11.26%) + D(108.9m)/V(1.15b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -10.01%
[DCF] Terminal Value 61.41% ; FCFF base≈28.7m ; Y1≈18.8m ; Y5≈8.62m
[DCF] Fair Price = 9.27 (EV 123.7m - Net Debt -303.1m = Equity 426.8m / Shares 46.1m; r=10.19% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 2.80 | EPS CAGR: -23.01% | SUE: -3.39 | # QB: 0
Revenue Correlation: 1.42 | Revenue CAGR: 0.56% | SUE: 0.05 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.24 | Chg7d=-0.002 | Chg30d=-0.002 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=0.78 | Chg7d=-0.003 | Chg30d=-0.003 | Revisions Net=-1 | Growth EPS=+52.0% | Growth Revenue=+4.4%
EPS next Year (2027-09-30): EPS=1.06 | Chg7d=+0.018 | Chg30d=+0.018 | Revisions Net=+1 | Growth EPS=+36.8% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.7% (Discount Rate 11.3% - Earnings Yield 2.6%)
[Growth] Growth Spread = -1.2% (Analyst 7.5% - Implied 8.7%)
External Resources
Dataroma Stockcircle